Hong Kong Registers Third COVID-19 Vaccine

Butantan Institute today announced the CoronaVac® Covid-19 received the definitive registration of use granted by the Hong Kong Department of Health on December 22, 2022. 

As a result, the immunizer was definitively registered in Asian territory as a pharmaceutical product for use from the age of three, following the rules of the Pharmacy and Poisons Board.

The Hong Kong Government announced earlier that a total of the three types of COVID-19 vaccines (Comirnaty ancestral strain vaccine (30 micrograms/dose), Comirnaty bivalent vaccine, and CoronaVac vaccine are being supplied in Hong Kong by two drug manufacturers, namely Fosun Pharma and Sinovac.

"The official registration of COVID-19 vaccines provided in Hong Kong reflects that the relevant vaccines are safe and efficacious and that the relevant supporting data is sufficient."

"Nevertheless, we call upon members of the public who have not yet received suitable doses of vaccine to get the suitable doses as soon as possible for self-protection, in particular high-risk persons such as the elderly and the young," the spokesman added in a press release.

Around the world, about 3 billion doses of CoronaVac have already been distributed in more than 60 countries. 

The vaccine was the first against Covid-19 to be applied to Brazilians, with 112 million doses delivered by Butantan by the beginning of 2023.